Lima M, Teixeira M dos A, Morais S, Cunha M, Coutinho J, Pinho L, Ribeiro P, Justiça B
Service of Clinical Hematology, S. Antonio's General Hospital, Porto, Portugal.
Sangre (Barc). 1995 Feb;40(1):49-52.
To analyse the immunophenotype of acute leukaemia (AL) after myelodysplastic syndromes (MDS) (MDS-AL) and to compare the immunophenotypic profile of acute myeloblastic leukaemia (AML) secondary to MDS (MDS-AML) with that of "de novo"-AML.
Twenty patients with MDS-AL and 29 patients with "de novo"-AML were studied. Morphocytochemical and flow cytometric studies were done in each case.
All the MDS-AL studied displayed a myeloid phenotype (MDS-AML). The main difference between MDS-AML and "de novo"-AML was a significantly higher frequency of CD34 expression in the first group. Differences concerning the expression of other non-lineage related or myeloid-associated markers were not statistically significant, although the percentage of cases CD15(+) was lower in MDS-AML. The overall frequency of expression of lymphoid-associated markers was similar in both groups, T-cell markers being more frequently detected.
Our findings support the usefulness of immunophenotyping studies to characterize MDS-AL and suggest some immunophenotyping differences between MDS-AML and "de novo"-AML which might have biological and prognostic significance.
分析骨髓增生异常综合征（MDS）后急性白血病（AL）（MDS-AL）的免疫表型，并比较MDS继发的急性髓系白血病（AML）（MDS-AML）与“原发性”AML的免疫表型特征。
研究了20例MDS-AL患者和29例“原发性”AML患者。对每例患者进行了形态细胞化学和流式细胞术研究。
所有研究的MDS-AL均表现为髓系表型（MDS-AML）。MDS-AML与“原发性”AML之间的主要差异在于第一组中CD34表达频率显著更高。尽管MDS-AML中CD15(+)病例的百分比更低，但其他非谱系相关或髓系相关标志物表达的差异无统计学意义。两组中淋巴系相关标志物的总体表达频率相似，T细胞标志物更常被检测到。
我们的研究结果支持免疫表型研究对MDS-AL进行特征描述的有用性，并提示MDS-AML与“原发性”AML之间存在一些可能具有生物学和预后意义的免疫表型差异。
